Controlled Substances Need Tamper-Proof Controlled Release, Report Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Manufacturers should include safeguard plans against prescription drug abuse in NDA materials, according to a report from Columbia's Center on Addiction & Substance Abuse. The report finds a marked increase in prescription drug abuse and concludes that DTC advertising and internet availability are contributing to the rise.
You may also be interested in...
Tarceva Pancreatic Cancer Indication Turned Down In The EU
Roche will consider requesting a re-examination of the negative decision by the Committee for Medicinal Products for Human Use.
Teva To Investigate High-Dose Copaxone
A Phase III trial will compare 40 mg/day glatiramer to the 20 mg/day approved dose.
J&J’s Velcade Is Not Cost-Effective For Multiple Myeloma, U.K.’s NICE Suggests
A National Institute for Health & Clinical Excellence analysis finds cost per quality-adjusted life year gained as high as $83,000.